These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 35760058)
1. Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma. Mikuteit M; Zschäbitz S; Erlmeier M; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F Oncology; 2022; 100(10):536-541. PubMed ID: 35760058 [TBL] [Abstract][Full Text] [Related]
2. Trophoblast Cell Surface Antigen 2 (Trop2) in Chromophobe Renal Cell Carcinoma. Mikuteit M; Steffens S; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Erlmeier F Oncology; 2022; 100(6):331-336. PubMed ID: 35168242 [TBL] [Abstract][Full Text] [Related]
3. The role of claudin-6 in chromophobe renal cell carcinoma. Erlmeier F; Zschäbitz S; Mikuteit M; Autenrieth M; Weichert W; Hartmann A; Steffens S Histol Histopathol; 2023 Apr; 38(4):403-407. PubMed ID: 36128931 [TBL] [Abstract][Full Text] [Related]
4. Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a Multicenter Cohort: Early Prognostic and Therapeutic Considerations. Mikuteit M; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F Oncology; 2024; 102(6):503-509. PubMed ID: 38043528 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma. Erlmeier M; Mikuteit M; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F BMC Urol; 2023 May; 23(1):90. PubMed ID: 37170275 [TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception? Erlmeier F; Hartmann A; Autenrieth M; Wiedemann M; Ivanyi P; Steffens S; Weichert W Med Oncol; 2016 Nov; 33(11):120. PubMed ID: 27696122 [TBL] [Abstract][Full Text] [Related]
7. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ; BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519 [TBL] [Abstract][Full Text] [Related]
8. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size. Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ; Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561 [TBL] [Abstract][Full Text] [Related]
9. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis. Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610 [TBL] [Abstract][Full Text] [Related]
10. c-Met in chromophobe renal cell carcinoma. Erlmeier F; Ivanyi P; Hartmann A; Autenrieth M; Wiedemann M; Weichert W; Steffens S Med Oncol; 2017 Feb; 34(2):15. PubMed ID: 28035577 [TBL] [Abstract][Full Text] [Related]
11. PD-L2: A prognostic marker in chromophobe renal cell carcinoma? Erlmeier F; Weichert W; Autenrieth M; Wiedemann M; Schrader AJ; Hartmann A; Ivanyi P; Steffens S Med Oncol; 2017 May; 34(5):71. PubMed ID: 28353093 [TBL] [Abstract][Full Text] [Related]
12. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Gustafsson A; Martuszewska D; Johansson M; Ekman C; Hafizi S; Ljungberg B; Dahlbäck B Clin Cancer Res; 2009 Jul; 15(14):4742-9. PubMed ID: 19567592 [TBL] [Abstract][Full Text] [Related]
15. DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma. Zhao W; Tian B; Wu C; Peng Y; Wang H; Gu WL; Gao FH Pathol Res Pract; 2015 Apr; 211(4):303-7. PubMed ID: 25596994 [TBL] [Abstract][Full Text] [Related]
16. Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms. Skala SL; Wang X; Zhang Y; Mannan R; Wang L; Narayanan SP; Vats P; Su F; Chen J; Cao X; Siddiqui J; Argani P; Cieślik MP; Giordano TJ; Chinnaiyan AM; Dhanasekaran SM; Mehra R Eur Urol; 2020 Jul; 78(1):63-74. PubMed ID: 32299640 [TBL] [Abstract][Full Text] [Related]
17. KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms. Petit A; Castillo M; Santos M; Mellado B; Alcover JB; Mallofré C Am J Surg Pathol; 2004 May; 28(5):676-8. PubMed ID: 15105658 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma. Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958 [TBL] [Abstract][Full Text] [Related]
19. The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma. Steffens S; Janssen M; Roos FC; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Hasenfus A; Kuczyk MA; Junker K; Schrader AJ; Hum Pathol; 2014 Dec; 45(12):2411-6. PubMed ID: 25305793 [TBL] [Abstract][Full Text] [Related]